Determining the Molecular Basis of Tumour Cell Multidrug Resistance: Structural and Functional Analysis of Breast Cancer Resistance Protein

确定肿瘤细胞多药耐药性的分子基础：乳腺癌耐药蛋白的结构和功能分析

• 批准号: nhmrc : 1053624
• 负责人: Dr Aaron Mcgrath
• 金额: $ 23.95万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/determining-molecular-basis-resistance-protein/112339
• 关键词: Determining; Molecular; Basis; Tumour; Cell

Around 40% of human tumours develop resistance to chemotherapeutic drugs; a trait most commonly acquired by the increased expression of membrane proteins that remove a broad spectrum of molecules from the cell. This project aims to determine the structure of the human breast cancer resistance protein (BCRP), a protein of particular importance in this process. The structure of BCRP will provide a scaffold for the design of drugs aimed at inhibiting chemotherapy drug resistance.

大约40%的人类肿瘤对化疗药物产生抗药性；这一特征最常见的获得方式是增加膜蛋白的表达，从而从细胞中移除广泛的分子。该项目旨在确定人类乳腺癌耐药蛋白(BCRP)的结构，这是一种在这一过程中特别重要的蛋白质。BCRP的结构将为设计旨在抑制化疗耐药的药物提供支架。